XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.13

-0.5%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Olu Emuleomo who started this subject	2/20/2004 9:47:44 PM
From: Robert K.	of 17367

I believe this is a new trial, note the words concomitant or transitioned from systemic. >Summary: A Phase IIIb Open-Label Multicenter Study to Evaluate the Safety of 1.0 mg/kg Efalizumab in Adults with Moderate to Severe Plaque Psoriasis The purpose of this study is to determine the safety of an investigational drug in the treatment of psoriasis that will be administered by a subcutaneous (under the skin) injection. This study will last approximately 12 weeks and 5 visits will be required. All participants will receive active drug in this study. No participants in this study will be receiving a placebo (inactive substance). Patient Inclusion/Exclusion Criteria: Subjects with plaque-type psoriasis between the ages of 18 and 75 years of age are eligible for participation in this study, including those who are receiving concomitant antipsoriatic therapies or have recently transitioned from systemic therapies. Pregnant females are not eligible. Other restrictions will be explained at the screening visit.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next